To determine the propensity of β-lactam antimicrobials to ameliorate or potentiate aminoglycoside-induced renal enzymuria.
DESIGN:
Two open, randomized, double-blind, parallel-group studies were conducted in young, healthy, male volunteer subjects. Using a common protocol, 24-hour urine collections were analyzed for the renal tubular enzymes alanine aminopeptidase (AAP) and N-acetyl-β-d-glucosaminidase (NAG), as well as for creatinine. Antimicrobial combinations studied included gentamicin plus placebo and gentamicin plus ticarcillin/clavulanate (protocol 1); and gentamicin plus placebo, gentamicin plus piperacillin, and gentamicin plus ceftazidime (protocol 2). The antimicrobial regimens were administered for 7 days. Eight subjects completed each treatment group.
RESULTS:
There were no significant differences between treatment groups with regard to urine creatinine excretion or serum gentamicin concentrations in either protocol. Enzymuria (AAP [p = 0.039] and NAG [p = 0.337]) was decreased in the gentamicin plus ticarcillin/clavulanate treatment compared with that in the gentamicin plus placebo treatment. Increased enzymuria, as indicated by increased urine concentrations of AAP and NAG, was observed in the gentamicin plus ceftazidime treatment (p < 0.05) compared with the other two treatments.
CONCLUSIONS:
Based on relative enzymuria, ticarcillin/clavulanate may be renal protective. Piperacillin neither potentiated nor ameliorated aminoglycoside-induced enzymuria. Since acute elevations in AAP and NAG reflect insults to the kidney, these studies suggest that ceftazidime may enhance aminoglycoside- induced renal injury. Piperacillin had no effect on enzymuria and would appear not to enhance or protect against aminoglycoside- induced renal injury.
De BroeMEGiulianoRAVerpootenGA. Aminoglycoside nephrotoxicity: Mechanism and prevention. Adv Exp Med Biol1989; 252: 233–45.
2.
MolitorisBAMeyerCDahlRGeerdesA. Mechanism of ischemia-enhanced aminoglycoside binding and uptake by proximal tubule cells. Am J Physiol1993; 264: F907–16.
3.
ThomasNToutainHDadounCMorinJPFillastreJP. Can piperacillin modify the experimental nephrotoxicity of gentamicin?Presse Med1986; 15: 2362–7.
4.
GibeyRDupondJHenryJ. Urinary N-acetyl-beta-d-glucosaminidase (NAG) isoenzyme profiles: A tool for evaluating nephrotoxicity of aminoglycosides and cephalosporins. Clin Chim Acta1984; 137: 1–11.
5.
GoldsteinRSSmithPFTarloffJBContardiLRushGLHookJB. Minireview: Biochemical mechanisms of cephaloridine nephrotoxicity. Life Sci1988; 42: 1809–16.
6.
MondorfAW. Comparative studies on the action of aminoglycosides and cephalosporins on the proximal tubule of the human kidney. Nouv Presse Med1978; 7: 3835–7.
7.
MondorfAW. Effect of cefoperazone alone and in combination with tobramycin on the proximal tubular membrane of the human kidney. Infection1981; 9 (Suppl 1):S30–3.
8.
TuneBM. Mechanism of the mitochondrial respiratory toxicity of cephalosporin antibiotics. Adv Exp Med Biol1989; 252: 313–8.
9.
TuneBMHsuCY. Toxicity of cephaloridine to carnitine transport and fatty acid metabolism in rabbit renal cortical mitochondria: Structure-activity relationships. J Pharmacol Exp Ther1994; 270: 873–80.
10.
BarzaM. The nephrotoxicity of cephalosporins: An overview. J Infect Dis1978; 137 (suppl):S60–73.
SchentagJJ. Specificity of renal tubular damage criteria for aminoglycoside nephrotoxicity in critically ill patients. J Clin Pharmacol1983; 23: 473–83.
14.
MondorfAWHeynoldFTScherberichJEHessHSchoeppeW. Assessment of the nephrotoxic potential of ceftazidime and a ceftazidime/tobramycin combination in volunteers. Infection1983; 11 (Suppl 1):S57–62.
15.
MondorfAWScherberichJEHeinertGSchoeppeW. Enzymuria: A parameter for the assessment of potential nephrotoxicity of cephalosporins. J Antimicrob Chemother1983; 12 (Suppl A):251–4.
16.
MondorfAWZegelmanMKloseJMaskeLScherberichJEStefanescu. Effects of various cephalosporins on the proximal tubule of the human kidney. Eur J Clin Pharmacol1978; 13: 357–63.
17.
MondorfAWBreierJHendusJSherberichJEMaCkenrodtGShahPM. Effect of aminoglycosides on proximal tubular membranes of the human kidney. Eur J Clin Pharmacol1978; 13: 133–42.
18.
SanderinkGJArturYSiestG. Human aminopeptidases: A review of the literature. J Clin Chem Clin Biochem1988; 26: 795–807.
Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram negative bacteremia in cancer patients with granulocytopenia.The EORTC International Antimicrobial Therapy Cooperative Group. N Engl J Med1987; 317: 1692–8.
21.
MooreRDSmithCRLietmanPS. The association of aminoglycoside plasma levels with mortality in patients with gram negative bactermia. J Infect Dis1984; 149: 443–8.
22.
VemuriRKZervosMJ. Enterococcal infection: The increasing threat of nosocomial spread and drug resistance. Postgrad Med1993; 93: 121–8.
23.
WadeJCPettyBGConradGSmithCRLipskyJJEllnerJ. Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside. Lancet1978; 2: 604–6.
24.
KlasterskyJHensgensCDebusscherL. Empiric therapy for cancer patients: Comparative study of ticarcillin—tobramycin, ticarcillin—cephalothin, and cephalothin—tobramycin. Antimicrob Agents Chemother1975; 7: 640–5.
25.
SteinGEMummawNDobraKSleightS. Amelioration of gentamicin nephrotoxicity with carbenicillin and piperacillin (abstract). J Clin Pharmacol1989; 29: 833.
26.
TrollforsBAlestigKRodjerSSandbergTWestinJ. Renal function in patients treated with tobramycin—cefuroxime or tobramycin—penicillin G. J Antimicrob Chemother1983; 12: 641–5.
27.
MondorfAWBonsiepeCMondorfW. Randomized multi center study comparing nephrotoxicity of ceftazidime versus the combination of piperacillin and netilmicin with and without furosemide. Adv Exp Med Biol1989; 252: 307–12.
28.
VerhoMMaabLMalerczykVGrotschH. Renal tolerance of cefpirome (HR 810) a new cephalosporin antibiotic. Infection1987; 15: 215–9.
29.
WellwoodJMPriceRGEllisBGThompsonAE. A note on the practical aspects of the assay of N-acetyl-β-d-glucosaminidase in human urine. Clin Chim Acta1976; 69: 85–91.
30.
MaruhnD. Rapid colorimetric assay of beta-galactosidase and N-acetyl-beta-glucosaminidase in human urine. Clin Chim Acta1976; 73: 453–61.
31.
JungKScholzD. An optimized assay of alanine aminopeptidase activity in urine. Clin Chem1980; 26: 1251–4.
32.
BennettWMWoodCAHoughtonDCGilbertDN. Modification of experimental aminoglycoside nephrotoxicity. Am J Kidney Dis1986; 8: 292–6.
33.
SabraRBranchRA. Role of sodium in protection by extended-spectrum penicillins against tobramycin-induced nephrotoxicity. Antimicrob Agents Chemother1990; 34: 1020–5.
34.
EnglishJGilbertDNKohlheppSKohnenPWMayorGHoughtonDC. Attenuation of experimental tobramycin nephrotoxicity by ticarcillin. Antimicrob Agents Chemother1985; 27: 897–902.
35.
HaleDCJenkinsRMatsenJM. In vitro inactivation of aminoglycoside antibiotics by piperacillin and carbenicillin. Am J Clin Pathol1980; 74: 316–9.
36.
BlairDCDugganDSchroederE. Inactivation of amikacin and gentamicin by carbenicillin in patients with end-stage renal failure. Antimicrob Agents Chemother1982; 22: 376–9.
37.
SchentagJJSimonsGWSchultzRWVanceJWWilliamsJS. Complexation versus hemodialysis to reduce elevated aminoglycoside serum concentrations. Pharmacotherapy1984; 4: 374–80.
38.
WilliamsPDHottendorfGHBennettDB. Inhibition of renal membrane binding and nephrotoxicity of aminoglycosides. J Pharmacol Exp Ther1986; 237: 919–25.
39.
FrenchMACerraFBPlautMESchentagJJ. Amikacin and gentamicin accumulation pharmacokinetics and nephrotoxicity in critically ill patients. Antimicrob Agents Chemother1981; 19: 147–52.
40.
De BroeMEVerbistLVerpootenGA. Influence of dosage schedule on renal cortical accumulation of amikacin and tobramycin in man. J Antimicrob Chemother1991; 27 (Suppl C):41–7.
41.
VerpootenGAGiulianoRAVerbistLEestermansGDe BroeME. Once-daily dosing decreases renal accumulation of gentamicin and netilmicin. Clin Pharmacol Ther1989; 45: 22–7.
42.
GregoryMHWellsDGPincottJR. A comparison of urinary N-acetyl-β-glucosaminidase and α1-microglobulin excretion with renal tubular morphology, and observation on their clinical significance. J Pharm Med1993; 3: 15–23.
43.
CalandraTZinnerSHViscoliCBockRGayaHMeunierF. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med1993; 119: 584–93.
